Search

Your search keyword '"Fauvel, J."' showing total 196 results
Start Over Author "Fauvel, J." Language english
196 results on '"Fauvel, J."'

15. Abdominal Aortic Calcifications Influences the Systemic and Renal Hemodynamic Response to Renal Denervation in the DENERHTN (Renal Denervation for Hypertension) Trial

Author

Pereira, Helena, Del Giudice, Costantino, Dourmap, Caroline, Azarine, Arshid, Azizi, Michel, Amar, L., Lorthioir, A., Monge, Matthieu, Pagny, J.‐Y., Claisse, G., Delsart, Pascal, Midulla, M., Mounier‐Vehier, Claire, Courand, Pierre-Yves, Dauphin, R., Fauvel, J., Lantelme, Pierre, Rouvière, O., CREMER, A., Gosse, Philippe, Grenier, N., Lebras, Y., Trillaud, H., Denolle, Thierry, Dourmap‐Collas, C., Heautot, J., Larralde, A., Paillard, F., Cluzel, P., Girerd, Xavier, Rosenbaum, D., Alison, D., Claudon, M., Popovic, B., Rossignol, Patrick, Ormezzano, Olivier, Thony, F., Bartoli, J., Vaisse, Bernard, Drouineau, J., Herpin, Daniel, Sosner, P., Tasu, J., Velasco, S., Ribstein, Jean, Bouhanick, Beatrice, Chamontin, B., Rousseau, H., Le Jeune, S., Lopez‐Sublet, M., Mourad, Jean‐Jacques, Bellmann, L., Esnault, V., Ferrari, Emile, Sapoval, Marc, Bobrie, Guillaume, Chatellier, Gilles, Plouin, P., Zannad, Faiez, Halimi, Jean Michel, Baguet, J., Kovacsik, H., Durand‐Zaleski, I., Beregi, J., Lièvre, M., Persu, A., Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

16. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease

Author

Torres, Vicente E., Chapman, Arlene B., Devuyst, Olivier, Gansevoort, Ron T., Perrone, Ronald D., Koch, Gary, Ouyang, John, Mcquade, Robert D., Blais, Jaime D., Czerwiec, Frank S., Sergeyeva, Olga, Reprise, Trial Investigators, Cowley, B., Goldstein, S., Chertow, G., Wei, L., Alpers, D. H., Freston, J., Lewis, J. H., Hunt, C. M., La Fuente, J., Vallejos, A., Beresan, H. M., Diaz, H. C., Wasserman, A., Martin, R. S., Rial, M., Cusumano, A. M., Novoa, P. A., Mele, P., Raffaele, P., Fraser, I., Rangan, G., Mathew, M., Cooper, B., Faull, R., Holt, S., Snelling, P., Jardine, M., Thomas, M., Packham, D., Vilayur, E., Johnson, D., Niepen, P., Peeters, P., Bammens, B., Warling, X., Vlem, B., Doubel, P., Hellemans, R., Bichet, D., Pei, Y., Chow, S., Mcmahon, A., Murphy, S., Mcfarlane, P., Ting, R., Tesar, V., Ryba, M., Peskova, M., Oplustilova, A., Dusilova Sulkova, S., Tocik, J., Suchanova, J., Viklicky, O., Rehorova, J., Valkovsky, I., Dieperink, H., Birn, H., Bech, J., Christensen, J., Zaoui, P., Pouteil-Noble, C., Combe, C., Kessler, M., Lemeur, Y., Mariat, C., Chauveau, D., Laville, M., Rieu, P., Fauvel, J. P., Dellanna, F., Gross, P., Renders, L., Budde, K., Sommerer, C., Strutz, F., Hugo, C., Guberina, H., Leidig, M., Csiky, B., Haris, A., Ondrik, Z., Kukuy, O., Ben-Dov, I., Yagil, Y., Schwartz, D., Dijk, D., Kristal, B., Capasso, G., Capelli, G., Cerutti, R., Esposito, C., Frascà, G., Gesualdo, L., Mancini, E., Manunta, P., Pontoriero, G., Scolari, F., Drenth, J., Apeland, T., Marti, H. P., Stenehjem, A., Klatko, W., Klinger, M., Ksiazek, A., Malecki, R., Nowicki, M., Sulowicz, W., Bako, G., Achim, C., Dragulete, R., Marasaev, V., Nagibovich, O., Rossovskaya, M., Esayan, A., Rayner, B., Latiff, G., Muranda, A., Peces Serrano, R., Nieto Iglesias, J., Hueso Val, M., Praga Terente, M., Castro Alonso, C., Guron, G., Melin, J., Heimbürger, O., Fernström, A., Hellberg, O., Turner, N., D Souza, R., Barratt, J., Mikhail, A., Howse, M., Sayer, J., Shipley, T., Takats, D., sunil bhandari, Ong, A., Hillman, K., Vilar, E., Wood, G., Gale, D., Kingswood, J., Ayub, W., Lambie, S., Al-Saghir, F., Bai, L., Price, D., Dilley, J., Blumenfeld, J., Scott, D., Sothinathan, R., Mehta, B., Kaveh, K., Dahl, N., Haastrup, A., Kopyt, N., Harper, K., Ross, D., El-Shahawy, M., Nachman, P., Bellovich, K., Shirazian, S., Bart, S., Fadem, S., Watnick, T., Oo, T., Rastogi, A., Silva, A., Sullivan, J., Thomas, J., Mrug, M., Nossuli, A., Mcgreal, K., Hariachar, S., Umanath, K., Vernace, M., Rosner, M., Newman, G., Levitski-Heikkila, T., Smith, M., Schmidt, R., Reddy, B., Linfert, D., Roppolo, M., Edelstein, C., Rahbari Oskoui, F., Chonchol, M., Germain, M., Gupta, A., Kant, K., Goldberg, S., Mordujovich, J., Moustafa, M., Lifland, H., Cangiano, J., Visger, J., Negrea, L., Berg, J., Culpepper, M., Goral, S., Radhakrishnan, J., Navarro, J., Ryu, J., Burgner, A., Solomon, R., Venuto, R., Pisoni, R., Charen, E., Chuang, P., Mangoo-Karim, R., Lioudis, M., Cohen, R., Park, M., Delong, M., Siddiqi, S., Bodell, M., Mccune, T., Mandayam, S., Foringer, J., Raina, R., Pitone, J., Quadrini, M., Nwakoby, I., Vo, N., and Liss, K.

Published
2017

17. PREDICTION OF CV EVENT IN DIABETIC NEPHROPATHY

Author

Fauvel, J., Joly, D., Choukroun, Gabriel, Dussol, B., Fiquet, B., Halimi, J. -M., Quere, S., Combe, C., Ducher, M., Institut des Sciences Chimiques de Rennes (ISCR), Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Ecole Nationale Supérieure de Chimie de Rennes (ENSCR)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), CHU Amiens-Picardie, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Centre de néphrologie et transplantation rénale [Hôpital de la Conception - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Pharmaceut, Med & Sci Affairs, Novartis, Diagnostics et imageries des procédés industriels (ENISE-DIPI), Ecole Nationale d'Ingénieurs de Saint Etienne (ENISE), Hospices Civils de Lyon (HCL), Ciblage thérapeutique en Oncologie (EA3738), Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016

18. Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease

Author

De Zeeuw, Dick, Akizawa, Tadao, Audhya, Paul, Bakris, George L., Chin, Melanie, Christ-Schmidt, Heidi, Goldsberry, Angie, Houser, Mark, Krauth, Melissa, Lambers Heerspink, Hiddo J., McMurray, John J., Meyer, Colin J., Parving, Hans-Henrik, Remuzzi, Giuseppe, Toto, Robert D., Vaziri, Nosratola D., Wanner, Christoph, Wittes, Janet, Wrolstad, Danielle, Chertow, Glenn M., Toto, B., McCullough, P., Ivanovich, P., Ketteler, M., Lachin, J., McGill, J., Agarwal, R., Anker, S., Arenillas, J. F., Januzzi, J., Jardine, A., Kasner, S., Kissela, B., Kolansky, D., Mann, J., Thadhani, R., Champion de Crespigny, P., Chan, D. T., D'Almeida, E., Fraser, I., Gray, N., Holt, S., Irish, A., Isbel, N., Kerr, P., Packham, D., Phoon, R., Pollock, C., Roger, S., Suranyi, M., Walker, R., Wittert, G., Yue, D., Balcke, P., Prager, R., Schernthaner, G., Sunder-Plassmann, G., Jadoul, M., Krzesinski, J. M., Peeters, P., Van der Niepen, P., Van Gaal, L., Van Vlem, B., Warling, X., Chow, S., Cournoyer, S., Dumas, R., Jolly, S., Levin, A., McMahon, A., Mehta, H., Ooi, T. C., Perkins, D., Roy, L., Sapir, D., Tam, P., Bartaskova, D., Hemzsky, L., Kubina, D., Szabo, M., Tesar, V., Combe, C., Faller, B., Fauvel, J. P., Halimi, J. M., Hourmant, M., Le Meur, Y., Urena-Torres, P., Zaoui, P., Al-Sarraf, S., Burst, V., Degenhardt, S., Kempe, H. P., Kleophas, W., Kosch, C., Krumme, B., Kuhlmann, M., Pistrosch, F., Rambausek, M., Schmidt-Guertler, H., Segiet, T., Sommerer, C., Vielhauer, V., Wanner, C., Beberashvili, I., Benchetrit, S., Herskovits, T., Karnieli, E., Levin-Iaina, N., Mosenzon, O., Tsur, A., van Dijk, D. J., Wainstein, J., Yagil, Y., Yerushalmi, Y., Colussi, G., Conte, G., Di Luca, M., Giovambatista, C., Messa, P., Pani, A., Pisani, A., Rapana, M. R., Ruggenenti, P., Villa, G., Zoccali, C., Correa-Rotter, R., Diaz-Escobedo, S. L., Garcia, P., Gonzalez Galvez, G., Obrador Vera, G. T., Rico, R., Calero, F., Cigarran, S., de Alvaro, F., de Francisco, A. L., Egido, J., Fernandez, E., Fernandez Vega, F., Fort, J., Galan Serrano, A., Gorriz Teruel, J. L., Martinez, I., Martinez Castelao, A., Munar, M. A., Navarro, J., Nieto, J., Osuna, A., Pascual, J., Portoles, J., Praga, M., Vallés, M., Fellstrom, B., Frisenette-Fich, C., Hadimeri, H., Stenvinkel, P., Svensson, M., Weiss, L., Adamson, K., Dornhorst, A., El Kossi, M., Gnudi, L., Hendry, B., Johnson, A., Joseph, F., Kalra, P., Marshall, S., Mikhail, A., Myint, K. S., Soran, H., Taal, M., Zehnder, D., Abbott, L., Acharya, A., Ahmed, Z., Aiello, J., Akom, M., Ali, S., Alzohaili, O., Anderson, L., Anderson, S., Anger, M., Appel, G., Arakaki, R. F., Arif, A., Assefi, A. R., Atray, N., Awad, A., Barranco, E., Belledonne, M. O., Belo, D., Bernardo, M., Bernstein, R., Bhalla, V., Bhatia, D., Black, R. M., Block, G., Blondin, J., Blumenthal, S. S., Bononi, P., Brantley, R. R., Bresssler, P., Broumand, V., Brusco, O., Buerkert, J., Burgos-Calderon, R., Campbell, R., Canas, G., Cangiano, J., Cherlin, R., Chilakapati, V., Comunale, R., Coyne, D., Crawford, P. W., Darwish, R., Deeb, W., Denker, P. S., Desai, S., Desouza, C., Diamond, S., Dixon, B. S., Durham, J. H., Eisner, G., Elder, J. G., El-Shahawy, M., Fadda, G., Fitz-Patrick, D., Fonseca, V., Fraser, N. J., Frei, G., Fried, L., Galindo-Ramos, E., Germain, M., Ghantous, W., Gilbert, J. M., Gillum, D., Godwin, J., Goel, A., Goldfarb, DS., Graf, R. J., Greenwood, T., Guasch, A., Hanna, A., Harper, K., Herman, T., Hilton, T., Hines, T., Hoggard, J., Hootkins, R., Huseman, R., Israelit, A., Jamal, A., Kant, K., Kaptein, E., Kathresal, A., Kaupke, J., Kaveh, K., Kaye, W., Keightley, G. E., Keith, K., Khairullah, Q., Kondle, V., Kopyt, N., Krishna, G., Lawrence, M. K., LeBeau, M., Leehey, D. J., Levine, M. M., Levinson, D., Lew, S. Q., Lewis, D., Linfert, D., Liss, K., Lund, R., Madeleine, P., Mahmood, K., Martin, E. R., Martinez, C., Mayeda, S. O., Mendez, R., Middleton, J., Molitch, M. E., Moncrief, J., Moustafa, M., Muoneke, R., Murray, A. V., Murugan, T. S., Nammour, T. M., Nassar, G., Navaneethan, S., Newman, J., Nossuli, A., Nwakoby, I., Osama, S., Ouseph, R., Parker, J., Parnes, E., Patel, N., Pergola, P., Perlman, A., Perry, R. G., Petrillo, R., Prabhakar, S., Purighalla, R. S., Quesada-Suarez, L., Rabiei, A., Raskin, P., Rastogi, A., Reisin, E., Rekhi, A., Rivera-Colon, L., Rizk, D., Rodelas, R., Roer, D., Rosas, S., Ross, D. L., Rovner, S., Sackel, H., Sader, S., Santos, P., Schmidt, R., Shafik, S., Shakeel, M., Sharon, Z., Silva, A. L., Silva, A., Singh, B., Smith, M., Solomon, R., Soman, S., Spinowitz, B., Sprague, S. M., Spry, L., Stonesifer, L., Streja, D., Suchinda, P., Sun, C., Thakar, C. V., Trespalacios, F., Tumlin, J. A., Van Buren, P., Vernace, M., Vicks, S., Warren, M., Weiss, D., Welker, J., Winston, J. A., Wombolt, D. G., Wood, M., Wu, M., Wynne, A., Yu, H., Zabaneh, R. I., Groningen Kidney Center (GKC), Methods in Medicines evaluation & Outcomes research (M2O), De Zeeuw, Dick, Akizawa, Tadao, Audhya, Paul, Bakris, George L., Chin, Melanie, Christ-Schmidt, Heidi, Goldsberry, Angie, Houser, Mark, Krauth, Melissa, Lambers Heerspink, Hiddo J., Mcmurray, John J., Meyer, Colin J., Parving, Hans-Henrik, Remuzzi, Giuseppe, Toto, Robert D., Vaziri, Nosratola D., Wanner, Christoph, Wittes, Janet, Wrolstad, Danielle, Chertow, Glenn M., Toto, B., Mccullough, P., Ivanovich, P., Ketteler, M., Lachin, J., Mcgill, J., Agarwal, R., Anker, S., Arenillas, J. F., Januzzi, J., Jardine, A., Kasner, S., Kissela, B., Kolansky, D., Mann, J., Thadhani, R., Champion de Crespigny, P., Chan, D. T., D'Almeida, E., Fraser, I., Gray, N., Holt, S., Irish, A., Isbel, N., Kerr, P., Packham, D., Phoon, R., Pollock, C., Roger, S., Suranyi, M., Walker, R., Wittert, G., Yue, D., Balcke, P., Prager, R., Schernthaner, G., Sunder-Plassmann, G., Jadoul, M., Krzesinski, J. M., Peeters, P., Van der Niepen, P., Van Gaal, L., Van Vlem, B., Warling, X., Chow, S., Cournoyer, S., Dumas, R., Jolly, S., Levin, A., Mcmahon, A., Mehta, H., Ooi, T. C., Perkins, D., Roy, L., Sapir, D., Tam, P., Bartaskova, D., Hemzsky, L., Kubina, D., Szabo, M., Tesar, V., Combe, C., Faller, B., Fauvel, J. P., Halimi, J. M., Hourmant, M., Le Meur, Y., Urena-Torres, P., Zaoui, P., Al-Sarraf, S., Burst, V., Degenhardt, S., Kempe, H. P., Kleophas, W., Kosch, C., Krumme, B., Kuhlmann, M., Pistrosch, F., Rambausek, M., Schmidt-Guertler, H., Segiet, T., Sommerer, C., Vielhauer, V., Wanner, C., Beberashvili, I., Benchetrit, S., Herskovits, T., Karnieli, E., Levin-Iaina, N., Mosenzon, O., Tsur, A., van Dijk, D. J., Wainstein, J., Yagil, Y., Yerushalmi, Y., Colussi, G., Conte, G., Di Luca, M., Giovambatista, C., Messa, P., Pani, A., Pisani, A., Rapana, M. R., Ruggenenti, P., Villa, G., Zoccali, C., Correa-Rotter, R., Diaz-Escobedo, S. L., Garcia, P., Gonzalez Galvez, G., Obrador Vera, G. T., Rico, R., Calero, F., Cigarran, S., de Alvaro, F., de Francisco, A. L., Egido, J., Fernandez, E., Fernandez Vega, F., Fort, J., Galan Serrano, A., Gorriz Teruel, J. L., Martinez, I., Martinez Castelao, A., Munar, M. A., Navarro, J., Nieto, J., Osuna, A., Pascual, J., Portoles, J., Praga, M., Vallés, M., Fellstrom, B., Frisenette-Fich, C., Hadimeri, H., Stenvinkel, P., Svensson, M., Weiss, L., Adamson, K., Dornhorst, A., El Kossi, M., Gnudi, L., Hendry, B., Johnson, A., Joseph, F., Kalra, P., Marshall, S., Mikhail, A., Myint, K. S., Soran, H., Taal, M., Zehnder, D., Abbott, L., Acharya, A., Ahmed, Z., Aiello, J., Akom, M., Ali, S., Alzohaili, O., Anderson, L., Anderson, S., Anger, M., Appel, G., Arakaki, R. F., Arif, A., Assefi, A. R., Atray, N., Awad, A., Barranco, E., Belledonne, M. O., Belo, D., Bernardo, M., Bernstein, R., Bhalla, V., Bhatia, D., Black, R. M., Block, G., Blondin, J., Blumenthal, S. S., Bononi, P., Brantley, R. R., Bresssler, P., Broumand, V., Brusco, O., Buerkert, J., Burgos-Calderon, R., Campbell, R., Canas, G., Cangiano, J., Cherlin, R., Chilakapati, V., Comunale, R., Coyne, D., Crawford, P. W., Darwish, R., Deeb, W., Denker, P. S., Desai, S., Desouza, C., Diamond, S., Dixon, B. S., Durham, J. H., Eisner, G., Elder, J. G., El-Shahawy, M., Fadda, G., Fitz-Patrick, D., Fonseca, V., Fraser, N. J., Frei, G., Fried, L., Galindo-Ramos, E., Germain, M., Ghantous, W., Gilbert, J. M., Gillum, D., Godwin, J., Goel, A., Goldfarb, Ds., Graf, R. J., Greenwood, T., Guasch, A., Hanna, A., Harper, K., Herman, T., Hilton, T., Hines, T., Hoggard, J., Hootkins, R., Huseman, R., Israelit, A., Jamal, A., Kant, K., Kaptein, E., Kathresal, A., Kaupke, J., Kaveh, K., Kaye, W., Keightley, G. E., Keith, K., Khairullah, Q., Kondle, V., Kopyt, N., Krishna, G., Lawrence, M. K., Lebeau, M., Leehey, D. J., Levine, M. M., Levinson, D., Lew, S. Q., Lewis, D., Linfert, D., Liss, K., Lund, R., Madeleine, P., Mahmood, K., Martin, E. R., Martinez, C., Mayeda, S. O., Mendez, R., Middleton, J., Molitch, M. E., Moncrief, J., Moustafa, M., Muoneke, R., Murray, A. V., Murugan, T. S., Nammour, T. M., Nassar, G., Navaneethan, S., Newman, J., Nossuli, A., Nwakoby, I., Osama, S., Ouseph, R., Parker, J., Parnes, E., Patel, N., Pergola, P., Perlman, A., Perry, R. G., Petrillo, R., Prabhakar, S., Purighalla, R. S., Quesada-Suarez, L., Rabiei, A., Raskin, P., Rastogi, A., Reisin, E., Rekhi, A., Rivera-Colon, L., Rizk, D., Rodelas, R., Roer, D., Rosas, S., Ross, D. L., Rovner, S., Sackel, H., Sader, S., Santos, P., Schmidt, R., Shafik, S., Shakeel, M., Sharon, Z., Silva, A. L., Silva, A., Singh, B., Smith, M., Solomon, R., Soman, S., Spinowitz, B., Sprague, S. M., Spry, L., Stonesifer, L., Streja, D., Suchinda, P., Sun, C., Thakar, C. V., Trespalacios, F., Tumlin, J. A., Van Buren, P., Vernace, M., Vicks, S., Warren, M., Weiss, D., Welker, J., Winston, J. A., Wombolt, D. G., Wood, M., Wu, M., Wynne, A., Yu, H., Zabaneh, R. I., de Zeeuw, D, Akizawa, T, Audhya, P, Bakris, Gl, Chin, M, Christ Schmidt, H, Goldsberry, A, Houser, M, Krauth, M, Lambers Heerspink, Hj, Mcmurray, Jj, Meyer, Cj, Parving, Hh, Remuzzi, G, Toto, Rd, Vaziri, Nd, Wanner, C, Wittes, J, Wrolstad, D, Chertow, Gm, Pisani, Antonio, De Zeeuw, D, Bakris, G, Lambers Heerspink, H, Mcmurray, J, Meyer, C, Parving, H, Toto, R, Vaziri, N, and Chertow, G.

Subjects
Male, medicine.medical_specialty, Intention to Treat Analysi, NF-E2-Related Factor 2, NEPHROPATHY, Urology, Renal function, Kaplan-Meier Estimate, Type 2 diabetes, Placebo, Article, Nephropathy, NRF2, Double-Blind Method, Cardiovascular Disease, Diabetes mellitus, Internal medicine, medicine, CKD, Treatment Failure, Bardoxolone methyl, Oleanolic Acid, Renal Insufficiency, Chronic, Aged, OUTCOMES, IRBESARTAN, ANALOGS, business.industry, Medicine (all), Hazard ratio, General Medicine, Middle Aged, medicine.disease, Weight Lo, Endocrinology, Diabetes Mellitus, Type 2, Diabetic Nephropathie, Kidney Failure, Chronic, Female, TRIAL, Stage 4 chronic kidney disease, business, Glomerular Filtration Rate, Human, RENAL EVENTS BEACON
Abstract

Background: Although inhibitors of the renin–angiotensin–aldosterone system can slow the progression of diabetic kidney disease, the residual risk is high. Whether nuclear 1 factor (erythroid-derived 2)–related factor 2 activators further reduce this risk is unknown. Methods: We randomly assigned 2185 patients with type 2 diabetes mellitus and stage 4 chronic kidney disease (estimated glomerular filtration rate [GFR], 15 to < 30 ml per minute per 1.73 m2 of body-surface area) to bardoxolone methyl, at a daily dose of 20 mg, or placebo. The primary composite outcome was end-stage renal disease (ESRD) or death from cardiovascular causes. Results: The sponsor and the steering committee terminated the trial on the recommendation of the independent data and safety monitoring committee; the median follow-up was 9 months. A total of 69 of 1088 patients (6%) randomly assigned to bardoxolone methyl and 69 of 1097 (6%) randomly assigned to placebo had a primary composite outcome (hazard ratio in the bardoxolone methyl group vs. the placebo group, 0.98; 95% confidence interval [CI], 0.70 to 1.37; P=0.92). In the bardoxolone methyl group, ESRD developed in 43 patients, and 27 patients died from cardiovascular causes; in the placebo group, ESRD developed in 51 patients, and 19 patients died from cardiovascular causes. A total of 96 patients in the bardoxolone methyl group were hospitalized for heart failure or died from heart failure, as compared with 55 in the placebo group (hazard ratio, 1.83; 95% CI, 1.32 to 2.55; P < 0.001). Estimated GFR, blood pressure, and the urinary albumin-to-creatinine ratio increased significantly and body weight decreased significantly in the bardoxolone methyl group, as compared with the placebo group. Conclusions: Among patients with type 2 diabetes mellitus and stage 4 chronic kidney disease, bardoxolone methyl did not reduce the risk of ESRD or death from cardiovascular causes. A higher rate of cardiovascular events with bardoxolone methyl than with placebo prompted termination of the trial. (Funded by Reata Pharmaceuticals; BEACON ClinicalTrials.gov number, NCT01351675.)

Published
2013

19. Can we identify response markers to antihypertensive drugs? First results from the Ideal Trial

Author

Gueyffier, F., Subtil, F., Bejan-Angoulvant, T., Zerbib, Y., Baguet, J. P., Boivin, J. M., Mercier, A., Leftheriotis, G., Gagnol, J. P., Fauvel, J. P., Giraud, C., Bricca, G., Maucort-Boulch, Delphine, Erpeldinger, S., Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), and Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV]Life Sciences [q-bio]
Published
2015

20. Renal denervation for treating hypertension: experience at the University Hospital in Lyon

Author

Courand, P. Y., Dauphin, R., Rouviere, O., Paget, V., Khettab, F., Bergerot, Cyrille, Harbaoui, B., Bricca, G., Fauvel, J. P., Lantelme, P., Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), and Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL)

Subjects
Male, [SDV]Life Sciences [q-bio], Hypertension/blood/complications/*surgery, Body Mass Index, Risk Factors, Blood Pressure Monitoring, Natriuretic Peptide, Ambulatory, Humans, Prospective Studies, Aged, University, Left Ventricular/etiology, Renal Artery/innervation/*surgery, Hypertrophy, Middle Aged, Denervation/methods, Hospitals, Treatment Outcome, Kidney/innervation, Female, France, Brain/blood, Peptide Fragments/blood, Biomarkers/blood, Follow-Up Studies
Abstract

International audience; AIM: We report the first experience of Lyon's university hospital regarding renal denervation to treat patients with resistant essential hypertension. PATIENTS AND METHODS: Over a one-year period, 17 patients were treated (12 men, 5 women) with renal denervation. Baseline characteristics were as follows: age 56.5+/-11.5 years, BMI 33+/-5kg/m(2) and ambulatory blood pressure 157+/-16/87+/-13mmHg with 4.2+/-1.5 anti-hypertensive treatment. RESULTS: We did not observe intra-operative or early complications. After a median follow-up of 3 months and with the same anti-hypertensive treatment, office systolic blood pressure (SBP) and diastolic blood pressure (DBP) decrease respectively of 20+/-15 (P\textless0.001) and 10+/-13mmHg (P=0.014) (n=17). After six months of follow-up, ambulatory blood pressure (ABPM) decrease of 17.5+/-14.9mmHg (P=0.027) for SBP and of 10.5+/-9.6mmHg (P=0.029) for DBP (n=6). Among these patients, five of them were controlled (ABPM inferior to 130/80mmHg) and electrical left ventricular hypertrophy indexes decreased: R wave in aVL lead of 4+/-3mm (P=0.031), Sokolow index of 3+/-3mm (P=0.205), Cornell voltage criterion of 9+/-7mm (P=0.027) and Cornell product of 1310+/-1104 (P=0.027). CONCLUSION: Our results are in accordance with data from other centers. On average blood pressure decreases significantly but important inter individual variations are observed. The procedure seems safe.

Published
2014

27. A simple and reliable method for rapid production and purification of Pseudomonas aeruginosa haemolytic phospholipase C.

Author

Dubuoix, A., Nieto, M., Fauvel, J., Chap, H., Marty, N., Salles, J.-P., and Gaits, F.

Subjects
PSEUDOMONAS aeruginosa, PHOSPHOLIPASE C, MICROBIAL virulence, INFLAMMATION, SCHIZOSACCHAROMYCES pombe, MICROBIAL enzymes
Abstract

a. dubouix, m. nieto, j. fauvel, h. chap, n. marty, j.-p. salles and f. gaits. 2004. To design a simple method to produce active recombinant Pseudomonas aeruginosa haemolytic phospholipase C (PLC). Pseudomonas aeruginosa PLC is a virulence factor mainly involved in inflammatory and cytotoxic responses. While ammonium sulphate purification requires large amounts of bacterial suspensions and leads to low yields, production of recombinant protein in Escherichia coli is no more successful because of frequent inclusion bodies and accumulation of inactive PLC in the periplasmic space. Using an inducible system based on the glucose-repressed inv1 promoter in the yeast Schizosaccharomyces pombe, we were able to produce up to 10 IU ml−1 of pure toxin within 24 h. This work describes the first method to easily get recombinant haemolytic PLC. This method provides a powerful tool to study the mechanisms leading to its cellular toxicity. [ABSTRACT FROM AUTHOR]

Published
2004
Full Text
View/download PDF

29. Renal elimination of amikacin and the aging process.

Author

Ducher, M., Maire, P., Cerutti, C., Bourhis, Y., Foltz, F., Sorensen, P., Jelliffe, R., and Fauvel, J-P.

Subjects
PHARMACOKINETICS, AGING
Abstract

Objective: Although amikacin is primarily eliminated via glomerular filtration, drug concentrations are not consistently predicted in all patients. To better describe the relationship between amikacin clearance and both age and renal function, we used a new heuristic approach involving statistical analysis of dependence.Design and Setting: Retrospective pharmacokinetic study using data from seven centres in France.Participants: 634 patients with sepsis aged between 18 and 98 years of age who received intravenous amikacin.Methods: Clearance of amikacin was modelled using the NonParametric EM algorithm for a two-compartment model (NPEM2) with intravenous infusion.Results: A total of 2499 serum amikacin determinations was available for analysis. The relationship between the clearance of amikacin and age was weak. Interestingly, the Z method, which filters data based on dependence criteria, selected data that were best fitted by a polynomial function (r = 0.90; p < 0.001). This representation of the polynomial function was similar to a previously proposed theoretical model describing covariations between the clearance of amikacin and age. However, the polynomial function applied to only 33% of the patients that were selected by the Z method. The correlation between the clearance of amikacin and renal function was also relatively low (r = 0.39). The Z method exhibited a continuous and strong dependence pattern between the clearance of amikacin and age for 49% of the patients.Conclusions: The Z methodology, which filters data using dependence criteria, confirms that age, renal function and amikacin clearance are strongly related, but only in less than half of a large sample of patients with sepsis without renal pathology. These results suggest that other variables should be taken into account in order to improve the description of the behaviour of amikacin. The Z methodology improved the classical description of relationships between variables, and should be applied to better select pertinent variables in pharmacokinetic studies. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

32. QT interval dispersion as a predictor of arrhythmic events in congestive heart failure.

Author

Galinier, M, Vialette, J.-C, Fourcade, J, Cabrol, P, Dongay, B, Massabuau, P, Boveda, S, Doazan, J.-P, Fauvel, J.-M, and Bounhoure, J.-P

Abstract

Aims Identification of patients with congestive heart failure at risk of sudden death remains problematic and few data are available on the prognostic implications of QT dispersion. We sought to assess the predictive value of QT dispersion for arrhythmic events in heart failure secondary to dilated cardiomyopathy or ischaemic heart disease. Methods and Results Twelve-lead ECGs calculated for QT dispersion, 24h Holter ECGs and signal-averaged ECGs were prospectively recorded in 205 heart failure patients in sinus rhythm. The 86 patients with ischaemic heart disease and the 119 with dilated cardiomyopathy were not significantly different as regards NYHA grades (51 vs 49% in grades III–IV), cardiothoracic ratio (57±7 vs 57±6%) and ejection fraction (28±8 vs 29±9%). The mean QT dispersion (66±29 vs 65±27ms), the frequency of non-sustained ventricular tachycardia (37 vs 38%) and ventricular late potentials (41 vs 40%) were not significantly different in patients with ischaemic or dilated cardiomyop-athy. QT dispersion was not significantly related to other arrhythmogenic markers. During follow-up (24±16 months), 66 patients died, 22 of them died suddenly and seven presented a spontaneous sustained ventricular tachycardia. In patients with dilated cardiomyopathy, in multivariate analysis, only a QT dispersion >80ms was an independent predictor of sudden death (RR: 4·9, 95% CI 1·4–16·8,P<0·02) and arrhythmic events (RR: 4·5, 95% CI 1·5–13·5,P<0·01). In patients with ischaemic heart disease, no studied parameter was found significantly related to sudden death or arrhythmic events. Conclusion: In congestive heart failure, abnormal QT dispersion can identify patients with dilated cardiomyopathy who are at high risk of arrhythmic events. [ABSTRACT FROM PUBLISHER]

Published
1998
Full Text
View/download PDF

33. Prognostic value of arrhythmogenic markers in systemic hypertension.

Author

Galinier, M., Balanescu, S., Fourcade, J., Dorobantu, M., Albenque, J. P., Massabuau, P., Doazan, J. P., Fauvel, J. M., and Bounhoure, J. P.

Abstract

Objective To evaluate the prognostic value of arrhythmogenic markers in hypertensive patients. Design Two hundred and fourteen hypertensive patients without symptomatic coronary disease, systolic dysfunction, electrolyte disturbances or anti-arrhythmic therapy were included. Recordings were made of 12-lead standard ECGs with calculations of QT interval dispersion, 24 h Holter ECGs (204 patients), echocardiography (187 patients) and signal-averaged ECGs (125 patients). Results Baseline data: echocardiographic left ventricular hypertrophy was found in 63 patients (33·7%), non-sustained ventricular tachycardia (Lown class IV b) in 33 patients (16·2%), ventricular late potentials in 27 patients (21·6%). Mortality: after a mean follow-up of 42·4±26·8 months, global mortality was 11·2% (24 patients), cardiac mortality 7·9% (17 patients), sudden death 4·2% (nine patients). Univariate analysis: predictors of global, cardiac and sudden death were age ≥65 years, ECG strain pattern, Lown class IV b and QT interval dispersion >80 ms (P≤0·01). Left ventricular mass index was closely related to cardiac mortality (P=0·002). Multivariate analysis: only Lown class IV b was an independent predictor of global (RR 2·6, 95% CI 1·2–6·0) and cardiac mortality (RR 3·5, 95% CI 1·2–9·7). Conclusion In hypertensive patients, non-sustained ventricular tachycardia has a prognostic value. [ABSTRACT FROM PUBLISHER]

Published
1997
Full Text
View/download PDF

34. Prognostic value of late potentials in patients with congestive heart failure.

Author

Galinler, M., Albenque, J.-P., Atchar, N., Fourcade, J., Massabuau, P., Doazan, J.-P., Legoanvic, C., Fauvel, J.-M., and Bounhoure, J.-P.

Abstract

To investigate whether detection of ventricular late potentials could provide prognostic information in patients with congestive heart failure with or without bundle branch block, we prospectively obtained a signal-averaged ECG from 151 patients with congestive heart failure, using specific criteria in 57 patients with bundle branch block. Late potentials were detected in 49 patients (32·5%); their incidence was not significantly different in patients without (3 1%; 29 patients) or with bundle branch block (35%; 20 patients). Late potentials were present in 25 of 73 patients (34%) with idiopathic dilated cardiomyopathy, in 20 of 57 patients (35%) with ischaemic cardiomyopathy and in four of 21 patients (19%) with hypertensive heart disease (ns). Age, NYHA class, ejection fraction and use of amiodarone were not statistically different among patients with or without late potentials. In contrast, patients with late potentials had more past episodes of sustained ventricular tachycardia (8·2% four patients) than those without late potentials (·9% two patients).Twenty four hour ambulatory ECGs were obtained in 135 patients (89%) Non-sustained ventricular tachycardia was not correlated with the presence of late potentials found in 45 of 88 patients (51%) without late potentials and in 29 of 47 patients (62%) with late potentials (ns). The mean follow-up was 27 ± 12 months; 51 patients died, 31 from progressive congestive heart failure and 13 suddenly; seven prospectively had sustained ventricular tachycardia. The total mortality rate, the cardiac mortality rate and sudden death risk were not significantly related to the presence of late potentials; their incidence were respectively 35% (36 patients), 32% (33 patients) and 10% (10 patients) in patients without late potentials and 31% (15 patients), 23% (11 patients) and 6% (three patients) in those without late potentials. The incidence of sustained ventricular tachycardia during follow-up was 2% (two patients) in patients without late potentials and l0% (five patients) in those with late potentials.The incidence of sustained ventricular tachycardia experienced by the patients before the study or seen during follow-up was significantly increased in the presence of late potentials: 18% (nine patients) vs 2% (two patients) in the absence of late potentials (P<0·001 Removal from the study of data from patients with bundle branch block, patients with severe congestive heart failure (NYHA 3 or 4) or patients taking amiodarone did not alter these results. Thus, signal-averaged ECG results only improved risk stratification for sustained ventricular tachycardia in patients with congestive heart failure and failed to identify patients at high risk for sudden death. [ABSTRACT FROM PUBLISHER]

Published
1996
Full Text
View/download PDF

40. Long-term treatment of congestive heart failure by Captopril: hemodynamic, biological and clinical effects.

Author

KAYANAKIS, J. G., FAUVEL, J. M., GIRAUD, P., and BOUNHOURE, J. P.

Abstract

Congestive heart failure is frequently associated with an increase in peripheral resistance induced by stimulation of the renin angiotensin system and of the sympathetic nervous system. The clinical, biological and hemodynamic effects of Captopril (SQ 14225), an oral inhibitor of angiotensin converting enzyme, were measured in 20 patients with heart failure poorly controlled by digitalis,diuretics and vasodilator therapy. After two months of Captopril administration from 150 to 250 mg per day, NYHA functional class improved from 34 to 206 (P<0.01). Heart rate decreased from 84.20 ± 17.46 to 76.26 ± 15.86 beats/min (mean ± standard error of the mean), (P<0.05). Mean arterial pressure was not significantly reduced from 89.25 ± 17.21 to 82.70 ± 10.86 mm Hg. Systemic vascular resistance decreased from 2234 ± 560 to 1680 ± 381 dynes scm (P<0.001), and pulmonary wedge pressure fell from 20.25 ± 7.10 to 14.60 ± 5.96 mm Hg fP<0.001). Cardiac index rose from 1.91 ± 0.41 to 2.37 ± 0.55 l/min/m (P<0.001) and stroke work index also increased from 23.62 ± 9.78 to 33.35 ± 14.48 g/syst/m. Plasma renin activity increased from 2.08 ± 2.99 to 6.73 ± 3.98 ng/mlh (P<0.001), and plasma aldosterone level fell from 21 ± 135 to 10.65 ± 4.16 ng/100 ml(P<0.01). Clinical improvement remained stable in seven patients for more than six months. In all cases theoptimal dose did not need to be altered because of lachyphylaxis. Side effects were rare because of the lowdoses used (mean = 200 mg). The results suggest that Captopril may be useful in the treatment of congestive heart failure. [ABSTRACT FROM PUBLISHER]

Published
1981
Full Text
View/download PDF

42. Echocardiographic diagnosis of mobile left ventricular tumour.

Author

Sabot, G, Fauvel, J M, and Bounhoure, J P

Abstract

Echocardiography detected a mobile left ventricular tumour. The tracing showed a cluster of echoes in the left ventricular outflow tract corresponding to the location of the tumour as confirmed by cineangiograms. At operation, a thrombus was discovered, attached to a chorda tendineae. [ABSTRACT FROM PUBLISHER]

Published
1979
Full Text
View/download PDF

48. Changes in exercise tolerance and resting haemodynamics during long-term treatment of heart failure with xamoterol.

Author

Kayanakis, J. G., Courtault, L., Fauvel, J. M., Boundhoure, J. P., and Snow, H. M.

Abstract

The long-term efficacy of xamoterol in improving effort capacity and haemodynamics was investigated in a study lasting 1 year in heart failure patients. Following a 3 month, double-blind period of treatment with xamoterol, patients continued therapy for a further 9 months. Exercise duration rose by 27% at 3 months and this improvement was maintained at 12 months. Similarly, the statistically significant increase in cardiac index and reduction in pulmonary wedge pressure and exercise heart rate persisted for 12 months. [ABSTRACT FROM PUBLISHER]

Published
1990
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results